Press Releases Medigene AG

Equities

MDG1

DE000A1X3W00

Market Closed - Xetra Other stock markets 16:36:23 03/05/2024 BST			5-day change	1st Jan Change
1.545 ^EUR	-0.32%		+2.66%	+1.31%

05-02	Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	CI
05-02	Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 targeted T Cell Receptor	05-03	AQ
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor	05-02	GL
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein	05-02	GL
Medigene : Quartely Statement 2024	04-26	PU
Medigene AG reports Financial Results and Business Update for Q1 2024	04-26	GL
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process	04-25	GL
Medigene to Present at Upcoming Scientific Conferences	04-17	GL
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	04-08	GL
Medigene AG Secures European Patent for its iM-TCR Technology	04-04	GL
Medigene : Statement on Corporate Governance 2023	03-28	PU
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update	03-28	GL
Medigene : Declaration of Conformity 2024	03-26	PU
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	03-19	GL
Medigene AG to report full year 2023 financial results on March 28, 2024	03-18	GL
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting	03-06	GL
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo	03-04	GL
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo	03-04	AQ
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies	02-29	GL
Medigene to Present at Upcoming Conferences	02-19	GL
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors	02-12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Medigene AG

Equities

MDG1

DE000A1X3W00

Press Releases

Filters